Boston Scientific SVP exercises RSUs, withholds shares

Boston Scientific SVP Emily Woodworth reported several equity transactions involving restricted stock units and common stock.

Rhea-AI Filing Summary

Boston Scientific SVP Emily Woodworth reported several equity transactions involving restricted stock units and common stock. On February 13–16, 2026, she exercised restricted stock units that convert into an equal number of Boston Scientific common shares, with individual transactions including 1,413, 661, and 637 units. Corresponding common stock entries show the same share amounts acquired at a stated price of $0.0000 per share, reflecting non-cash derivative exercises. Additional common stock entries coded “F” cover 690, 296, and 283 shares delivered at $74.73 per share to satisfy tax liabilities rather than open-market sales. Footnotes state that each restricted stock unit represents a commitment to issue one share of common stock, generally in four equal annual installments beginning on specific grant anniversaries.

Insider Trade Summary

2,711 shares exercised/converted

Exercise 9 txns

Insider Woodworth Emily

Role SVP, Global Controller and CAO

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	637	$0.00	$0.00
Exercise	Common Stock	637	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	283	$74.73	$21K
Exercise	Restricted Stock Units	661	$0.00	$0.00
Exercise	Common Stock	661	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	296	$74.73	$22K
Exercise	Restricted Stock Units	1,413	$0.00	$0.00
Exercise	Common Stock	1,413	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	690	$74.73	$52K

Holdings After Transaction: Restricted Stock Units — 4,900 contracts (Direct); Common Stock — 2,393 shares (Direct)

Footnotes (4)

1. F1. Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
2. F2. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant.
3. F3. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant.
4. F4. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Boston Scientific (BSX) report for Emily Woodworth?

Boston Scientific reported that SVP Emily Woodworth exercised restricted stock units into common stock and had some shares withheld to cover tax obligations. The transactions occurred over February 13–16, 2026 and involved both derivative and non-derivative securities.

How many Boston Scientific (BSX) restricted stock units did the SVP convert?

The filing shows Woodworth exercised restricted stock units in separate transactions of 1,413, 661, and 637 units. Each restricted stock unit represents a commitment to issue one share of Boston Scientific common stock, according to the footnotes included in the report.

Were any of Emily Woodworth’s Boston Scientific (BSX) transactions open-market sales?

The transactions coded “F” in the filing reflect shares delivered to pay tax liabilities, not open-market sales. These covered 690, 296, and 283 common shares at a stated price of $74.73 per share, consistent with tax-withholding dispositions.

What do the restricted stock unit footnotes mean for Boston Scientific (BSX) shares?

Footnotes explain that each restricted stock unit equals one share of Boston Scientific common stock. Shares are scheduled to be issued in four equal annual installments beginning on specific grant anniversaries, such as February 13, 2026, depending on the original grant date.

What role does Emily Woodworth hold at Boston Scientific (BSX)?

The reporting person, Emily Woodworth, is identified as SVP, Global Controller and CAO of Boston Scientific. Her position as a senior officer requires reporting these equity transactions on Form 4 to provide transparency about her holdings in the company.

How did these Boston Scientific (BSX) transactions affect Woodworth’s direct ownership?

The filing shows her direct common stock ownership changing with each transaction, with share balances reported after every entry. For example, one line shows 2,393 common shares directly owned following a tax-withholding disposition coded “F” on February 16, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/18/2026 - 05:58 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Woodworth Emily

(Last) (First) (Middle)

300 BOSTON SCIENTIFIC WAY

(Street)

MARLBOROUGH MA 01752-1234

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BOSTON SCIENTIFIC CORP [ BSX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Global Controller and CAO

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/13/2026		M		1,413	A	$0.0000(1)	2,364	D
Common Stock	02/13/2026		F		690	D	$74.73	1,674	D
Common Stock	02/14/2026		M		661	A	$0.0000(1)	2,335	D
Common Stock	02/14/2026		F		296	D	$74.73	2,039	D
Common Stock	02/16/2026		M		637	A	$0.0000(1)	2,676	D
Common Stock	02/16/2026		F		283	D	$74.73	2,393	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/13/2026		M			1,413	(2)	02/13/2029(2)	Common Stock	1,413	$0.0000	4,239	D
Restricted Stock Units	(1)	02/14/2026		M			661	(3)	02/14/2027(3)	Common Stock	661	$0.0000	661	D
Restricted Stock Units	(1)	02/16/2026		M			637	(4)	02/16/2026(4)	Common Stock	637	$0.0000	0.0000	D

Explanation of Responses:

1. Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

2. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant.

3. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant.

4. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant.

	/s/ Susan Thompson, Attorney-in-Fact	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.